The studies using POPC with the MDCO-216 formulation (ApoA-IM-POPC) reported a profound increase in ABCA-1 mediated cholesterol efflux in healthy and stable CAD patients [39,245,246,247]. This evidence concerns the gene APOA1 and coronary artery disorder.